CA2318215A1 - Inhibition de l'agregation plaquettaire au moyen d'une combinaison d'heparine a faible poids moleculaire et d'antagoniste de recepteur de gp iib/iiia - Google Patents

Inhibition de l'agregation plaquettaire au moyen d'une combinaison d'heparine a faible poids moleculaire et d'antagoniste de recepteur de gp iib/iiia Download PDF

Info

Publication number
CA2318215A1
CA2318215A1 CA002318215A CA2318215A CA2318215A1 CA 2318215 A1 CA2318215 A1 CA 2318215A1 CA 002318215 A CA002318215 A CA 002318215A CA 2318215 A CA2318215 A CA 2318215A CA 2318215 A1 CA2318215 A1 CA 2318215A1
Authority
CA
Canada
Prior art keywords
molecular weight
low molecular
weight heparin
therapeutically effective
safe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002318215A
Other languages
English (en)
Inventor
Jacquelynn J. Cook
Robert J. Gould
Frederic L. Sax
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809793.4A external-priority patent/GB9809793D0/en
Application filed by Individual filed Critical Individual
Publication of CA2318215A1 publication Critical patent/CA2318215A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne un procédé relatif à l'inhibition de l'agrégation plaquettaire chez un mammifère, qui consiste à administrer à ce mammifère une quantité sûre et thérapeutiquement efficace d'antagoniste de récepteur de GP IIb/IIIa ou un sel pharmaceutiquement acceptable dudit antagoniste, en combinaison avec une quantité sûre et thérapeutiquement efficace d'héparine à faible poids moléculaire. L'invention concerne également un procédé relatif à l'inhibition de l'agrégation plaquettaire chez un mammifère, qui consiste à administrer à ce mammifère une quantité sûre et thérapeutiquement efficace d'acide propionique-(2-S-(n-butylsulfonylamino)-3[4-(pipéridine-4-yl)butyloxyphényl] ou un sel pharmaceutiquement acceptable dudit produit, en combinaison avec une quantité sûre et thérapeutiquement efficace d'héparine à faible poids moléculaire.
CA002318215A 1998-02-02 1999-01-29 Inhibition de l'agregation plaquettaire au moyen d'une combinaison d'heparine a faible poids moleculaire et d'antagoniste de recepteur de gp iib/iiia Abandoned CA2318215A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7342698P 1998-02-02 1998-02-02
US60/073,426 1998-02-02
GB9809793.4 1998-05-07
GBGB9809793.4A GB9809793D0 (en) 1998-05-07 1998-05-07 Platelet aggregation inhibition
PCT/US1999/002035 WO1999038827A1 (fr) 1998-02-02 1999-01-29 INHIBITION DE L'AGREGATION PLAQUETTAIRE AU MOYEN D'UNE COMBINAISON D'HEPARINE A FAIBLE POIDS MOLECULAIRE ET D'ANTAGONISTE DE RECEPTEUR DE GP IIb/IIIa

Publications (1)

Publication Number Publication Date
CA2318215A1 true CA2318215A1 (fr) 1999-08-05

Family

ID=26313621

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318215A Abandoned CA2318215A1 (fr) 1998-02-02 1999-01-29 Inhibition de l'agregation plaquettaire au moyen d'une combinaison d'heparine a faible poids moleculaire et d'antagoniste de recepteur de gp iib/iiia

Country Status (5)

Country Link
EP (1) EP1068172A4 (fr)
JP (1) JP2002501936A (fr)
AU (1) AU740941B2 (fr)
CA (1) CA2318215A1 (fr)
WO (1) WO1999038827A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
CA2364252A1 (fr) 1999-03-11 2000-09-14 Bristol-Myers Squibb Pharma Company Synergie entre l'heparine a faible masse moleculaire et des inhibiteurs d'agregation plaquettaire permettant d'elaborer une polytherapie pour la prevention et le traitement de divers troubles thromboemboliques
AU766089B2 (en) * 1999-03-11 2003-10-09 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin
US6518244B2 (en) * 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US6770660B2 (en) 2002-05-06 2004-08-03 Artery Llc Method for inhibiting platelet aggregation
EP1574516A1 (fr) * 2004-03-05 2005-09-14 Sanofi-Aventis Composés antithrombotiques
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
CA2624867A1 (fr) * 2005-10-10 2007-04-19 N.V. Organon Compose antithrombotique
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN112569184A (zh) * 2020-12-30 2021-03-30 山东裕欣药业有限公司 一种盐酸替罗非班注射液及制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
PH25458A (en) * 1987-08-24 1991-07-01 Eisai Co Ltd Piperidine derivatives, therapeutic, preventive agents
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
AU2340997A (en) * 1996-03-27 1997-10-17 Merck & Co., Inc. A method for inhibiting clot formation

Also Published As

Publication number Publication date
AU2350699A (en) 1999-08-16
EP1068172A1 (fr) 2001-01-17
JP2002501936A (ja) 2002-01-22
EP1068172A4 (fr) 2006-09-27
AU740941B2 (en) 2001-11-15
WO1999038827A1 (fr) 1999-08-05

Similar Documents

Publication Publication Date Title
US6511968B1 (en) Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
EP1392329B1 (fr) Utilisation de sulodexide pour le traitement d'une maladie enterique inflammatoire
AU723315B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6403571B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
AU2002304265A1 (en) Use of sulodexide for the treatment of inflammatory bowel disease
RU2252783C2 (ru) Фармацевтический препарат, содержащий низкомолекулярный ингибитор тромбина и его пролекарство
US6251852B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6136794A (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
US6518244B2 (en) Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
WO1997035579A1 (fr) Procede d'inhibition de la formation de caillots
WO1999045913A1 (fr) Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
ZA200106360B (en) Treatment of thrombosis by combined use of a factor XA inhibitor and aspirin, tissue plasminogen activator (TPA), a GPIIb/IIIa antagonist, low molecular weight heparin or heparin.
GB2332373A (en) Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
US5978698A (en) Angioplasty procedure using nonionic contrast media
WO1997035615A1 (fr) Compositions et techniques d'inhibition de la formation de caillots
US5980951A (en) Oral coated active drugs
EP0914099A1 (fr) Medicaments actifs enrobes a administration orale
GB2318053A (en) Angioplasty procedure using nonionic contrast media
AU2002248566A1 (en) Combinations of heparin cofactor II agonist and platelet IIB/IIIA antagonist, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead